RYZB News: Johnson Fistel Investigates Proposed Sale of RayzeBio; Is $62.50 a Fair Price?
December 26, 2023 09:23 ET
|
Johnson Fistel, LLP
On December 26, 2023, RayzeBio announced that it had entered a deal with Bristol Myers Squibb.
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of MyoKardia, Inc. Buyout
October 05, 2020 21:00 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating MyoKardia, Inc. (“MyoKardia”) (NASDAQ GS: MYOK) regarding possible breaches of...
Advantagene Announces Clinical Trial Collaboration
April 27, 2018 07:00 ET
|
Advantagene, Inc.
AUBURNDALE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Advantagene, Inc. today announced that the company entered into a clinical trial collaboration with Bristol-Myers Squibb (NYSE:BMY) to evaluate...
FDA Approves ABRAXANE(R) for Pancreatic Cancer, Could Nuvilex's Treatment Be Next
September 09, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 9, 2013) - After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of...
Drug Makers Could Soon Turn Away From Eli Lilly's Gemzar and Toward Nuvilex's Cell Encapsulation
August 22, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 22, 2013) - While Eli Lilly's cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big...